Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Mon, 06.02.2023
Cenit AG
First acquisition of 2023 strengthens EIM segment; price target and rating
unchanged
On 30 January 2023, CENIT AG announced the acquisition of 100% of the
Munich-based mip Management Informations Partner GmbH (mip for short). The
acquisition of mip, which will be retroactively consolidated into the CENIT
Group as of 1 January 2023, will fur [ … ]
Fri, 03.02.2023
The NAGA Group AG
First positive effects from initiated restructuring visible; Break-even
expected in the current financial year; Target price: € 3.60; Rating: BUY
Communication with the financial market of NAGA Group AG (NAGA for short)
in the past 2022 financial year was characterised by the postponement of
the 2021 annual report. Part of the delay wa [ … ]
Fri, 03.02.2023
The NAGA Group AG
First positive effects from initiated restructuring visible; Break-even
expected in the current financial year; Target price: € 3.60; Rating: BUY
Communication with the financial market of NAGA Group AG (NAGA for short)
in the past 2022 financial year was characterised by the postponement of
the 2021 annual report. Part of the delay wa [ … ]
Thu, 02.02.2023
PNE AG
First Berlin Equity Research hat ein Research Update zu PNE AG (ISIN:
DE000A0JBPG2) veröffentlicht. Analyst Dr. Karsten von Blumenthal stuft die
Aktie auf BUY herauf und bestätigt sein Kursziel von EUR 26,00.
Zusammenfassung:
Morgan Stanley Infrastructure/Photon Management führen keine Gespräche mehr
mit potenziellen Interess [ … ]
Thu, 02.02.2023
PNE AG
First Berlin Equity Research hat ein Research Update zu PNE AG (ISIN:
DE000A0JBPG2) veröffentlicht. Analyst Dr. Karsten von Blumenthal stuft die
Aktie auf BUY herauf und bestätigt sein Kursziel von EUR 26,00.
Zusammenfassung:
Morgan Stanley Infrastructure/Photon Management führen keine Gespräche mehr
mit potenziellen Interess [ … ]
Wed, 01.02.2023
Klondike Gold Corp.
First Berlin Equity Research hat ein Research Update zu Klondike Gold Corp.
(ISIN: CA4989033010) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und bestätigt sein Kursziel von CAD 0,85.
Zusammenfassung:
Wir glauben nun, dass Klondike Gold Corp auf dem besten Weg ist, bis JE24 2
Moz Au abzugrenzen, was das Unte [ … ]
Wed, 01.02.2023
Klondike Gold Corp.
First Berlin Equity Research hat ein Research Update zu Klondike Gold Corp.
(ISIN: CA4989033010) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und bestätigt sein Kursziel von CAD 0,85.
Zusammenfassung:
Wir glauben nun, dass Klondike Gold Corp auf dem besten Weg ist, bis JE24 2
Moz Au abzugrenzen, was das Unte [ … ]
Wed, 01.02.2023
Eloro Resources Ltd.
Highest and most extensive silver grades intersected
Eloro Resources announced assay results from eight more diamond drill holes
from its drilling programme at the Iska Iska silver-tin polymetallic
project in the Potosi Department, South Bolivia. With consistent high
silver grades averaging 69.80g Ag/t over a length of 325.48m in drill hole [ … ]
Wed, 01.02.2023
Eloro Resources Ltd.
Highest and most extensive silver grades intersected
Eloro Resources announced assay results from eight more diamond drill holes
from its drilling programme at the Iska Iska silver-tin polymetallic
project in the Potosi Department, South Bolivia. With consistent high
silver grades averaging 69.80g Ag/t over a length of 325.48m in drill hole [ … ]
Wed, 25.01.2023
Spexis AG
First Berlin Equity Research has initiated coverage on Spexis AG (ISIN:
CH0106213793). Analyst Christian Orquera's rating is BUY with a price
target of CHF 1.80.
Abstract:
Spexis AG is a biotech company with a clinical-stage product pipeline
focused on rare diseases and oncology. Spexis is the result of the merger
of the rare diseases specialist [ … ]
